Parallel Advisors’s ADMA Biologics ADMA Stock Holding History

Parallel Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.29K	Buy	751 +250	+50%	+$2.28K	﹤0.01%	3132
2026 Q1	$4.51K	Buy	501 +51	+11%	+$805	﹤0.01%	3072
2025 Q4	$8.21K	Buy	450 +29	+7%	+$489	﹤0.01%	2686
2025 Q3	$6.17K	Sell	421 -131	-24%	-$2.25K	﹤0.01%	2705
2025 Q2	$10.1K	Buy	552 +32	+6%	+$653	﹤0.01%	2475
2025 Q1	$10.3K	Buy	520 +66	+15%	+$1.14K	﹤0.01%	2424
2024 Q4	$7.79K	Buy	454 +21	+5%	+$395	﹤0.01%	2492
2024 Q3	$8.66K	Buy	433 +65	+18%	+$1.01K	﹤0.01%	2444
2024 Q2	$4.11K	Buy	368 +128	+53%	+$1.07K	﹤0.01%	2592
2024 Q1	$1.58K	Hold	240	–	–	﹤0.01%	2858
2023 Q4	$1.08K	Sell	240 -721	-75%	-$2.67K	﹤0.01%	2917
2023 Q3	$3.44K	Hold	961	–	–	﹤0.01%	2634
2023 Q2	$3.55K	Hold	961	–	–	﹤0.01%	2555
2023 Q1	$3.18K	Buy	961 +120	+14%	+$415	﹤0.01%	2585
2022 Q4	$3.26K	Hold	841	–	–	﹤0.01%	2495
2022 Q3	$2K	Buy	+841	New	+$2.02K	﹤0.01%	2569
2022 Q2	–	Sell	-11,954	Closed	-$22K	–	2947
2022 Q1	$22K	Buy	+11,954	New	+$18.6K	﹤0.01%	1674

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Parallel Advisors's ADMA Position: Q2 2026 in Review

Parallel Advisors increased its ADMA Biologics (ADMA) stake by 50% in Q2 2026, buying an estimated $2.28K and bringing the position to 751 shares worth $6.29K. The position accounts for ﹤0.01% of the portfolio, ranked #3132.

Parallel Advisors first reported a position in ADMA in Q1 2022 and has held it in 17 quarters since. The position peaked at $22K in Q1 2022. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Parallel Advisors held 751 shares of ADMA Biologics worth $6.29K as of Q2 2026.
Parallel Advisors bought 250 ADMA Biologics shares in Q2 2026, an estimated $2.28K.
ADMA Biologics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3132 holding.
Parallel Advisors first reported a position in ADMA Biologics in Q1 2022 and has held it in 17 quarters since.
Parallel Advisors's ADMA Biologics position peaked at $22K in Q1 2022.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.